Omeros’ (OMER) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Omeros (NASDAQ:OMER) in a report released on Thursday,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

OMER has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. HC Wainwright upped their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a report on Wednesday, October 15th. Finally, Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Trading Down 7.1%

Shares of OMER opened at $12.49 on Thursday. The stock has a market cap of $885.54 million, a P/E ratio of -6.18 and a beta of 2.38. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The stock’s 50-day moving average price is $10.58 and its two-hundred day moving average price is $6.66.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. As a group, equities analysts forecast that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its position in shares of Omeros by 9.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock valued at $545,000 after acquiring an additional 2,631 shares during the period. Harbour Investments Inc. raised its holdings in shares of Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares during the period. Russell Investments Group Ltd. lifted its stake in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares during the last quarter. Rhumbline Advisers grew its holdings in Omeros by 7.1% during the third quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 7,048 shares during the period. Finally, Cypress Capital Group increased its position in Omeros by 20.7% during the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 7,200 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.